Screening for human ADME/Tox drug properties in drug discovery

被引:433
作者
Li, AP [1 ]
机构
[1] In Vitro Technol, Baltimore, MD 21227 USA
关键词
D O I
10.1016/S1359-6446(01)01712-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There is no doubt that ADME/Tox drug properties, absorption, distribution, metabolism, elimination and toxicity, are properties crucial to the final clinical success of a drug candidate. It has been estimated that nearly 50% of drugs fail because of unacceptable efficacy, which includes poor bioavailability as a result of ineffective intestinal absorption and undesirable metabolic stability(1). It has also been estimated that up to 40% of drug candidates have failed in the past because of safety issues(2). In this review, the methodologies that are available for use in drug development as in vitro human-based screens for ADME/Tox drug properties are discussed.
引用
收藏
页码:357 / 366
页数:10
相关论文
共 25 条
[1]  
BORCHARDT RT, 1991, NATO ADV SCI I A-LIF, V218, P1
[2]   SUCCESS RATES FOR NEW DRUGS ENTERING CLINICAL-TESTING IN THE UNITED-STATES [J].
DIMASI, JA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) :1-14
[3]  
*FDA, 1992, JAMA-J AM MED ASSOC, V268, P705
[4]  
HILDAGO IJ, 1989, GASTROENTEROLOGY, V96, P736
[5]   FLUOROMETRIC METHOD FOR DETERMINATION OF OXIDIZED AND REDUCED GLUTATHIONE IN TISSUES [J].
HISSIN, PJ ;
HILF, R .
ANALYTICAL BIOCHEMISTRY, 1976, 74 (01) :214-226
[6]   Managing the drug discovery/development interface [J].
Kennedy, T .
DRUG DISCOVERY TODAY, 1997, 2 (10) :436-444
[7]   The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions [J].
Lehmann, JM ;
McKee, DD ;
Watson, MA ;
Willson, TM ;
Moore, JT ;
Kliewer, SA .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (05) :1016-1023
[8]  
Li A P, 1997, Adv Pharmacol, V43, P103, DOI 10.1016/S1054-3589(08)60203-3
[9]   Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential [J].
Li, AP ;
Lu, C ;
Brent, JA ;
Pham, C ;
Fackett, A ;
Ruegg, CE ;
Silber, PM .
CHEMICO-BIOLOGICAL INTERACTIONS, 1999, 121 (01) :17-35
[10]  
Li AP, 1999, BRIT J CLIN PHARMACO, V48, P733